Search Results

ProLung, Inc. dba IONIQ Sciences, Inc. announced that Mr. Jared Bauer, CEO, will present in-person at the 13th annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on June 6-8, 2023.

ProLung, Inc. dba IONIQ Sciences, Inc. announced it is presenting in person at Biotech Showcase™, the investor conference for innovators.

ProLung, Inc. dba IONIQ Sciences, Inc. today announced it is presenting at BioFuture and also providing an on-demand company presentation.

IONIQ Sciences Inc., which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics technology and a proprietary algorithm, announced it is changing its name from ProLung, Inc. to IONIQ Sciences, Inc.

ProLung, Inc. dba IONIQ Sciences, Inc. unveiled its next-generation platform called LUNA3™ for early-stage cancer detection.

Todd Morgan, the former Chairman of the Board of Directors (the “Board”) of ProLung, Inc. (“ProLung” or, the “Company”), together with a group of shareholders collectively owning approximately 16.3% of the outstanding common stock of ProLung (the “Group”) and led by ProLung’s former President, CEO and director Steven Eror, delivered an encouraging message to ProLung shareholders today regarding the Group’s consent solicitation

Delivers Letter to ProLung Requesting the Board to Establish a Record Date for the Consent Solicitation

Epi proLung is a highly innovative lung cancer test based on the combination of Epigenomics’ proprietary DNA methylation biomarkers.

Steven C. Eror, the Co-Founder and Former President, CEO and member of the Board of Directors (the “Board”) of ProLung, Inc., together with a group of stockholders (the “Group”) collectively owning approximately 16.3% of the outstanding common stock of ProLung, issued the following statements today on behalf of the Group regarding its consent solicitation to enlarge and enhance the Board.